Marianne Kristiansen Kringen

Papers

Total Citations

H-Index

About

Dr. Marianne Kristiansen Kringen is a leading researcher in pharmacogenomics, with a primary focus on the genetic determinants of warfarin dosing and anticoagulation therapy. Her seminal 2008 study, "Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction," has garnered 22 citations and established a critical foundation for personalized medicine in cardiovascular care. This work demonstrated how genetic variations in the CYP2C9 metabolizing enzyme and the VKORC1 vitamin K-activating enzyme significantly influence individual warfarin dosage requirements and international normalized ratio (INR) outcomes. By elucidating these genotype-phenotype correlations, Dr. Kringen has contributed to safer, more effective anticoagulation strategies, reducing the risk of adverse events in patients with myocardial infarction. Her research bridges the gap between molecular genetics and clinical practice, offering actionable insights for optimizing warfarin therapy. Dr. Kringen’s contributions are particularly notable for their direct translational impact, helping clinicians tailor treatments to individual genetic profiles. Her work remains a cornerstone in the field of cardiovascular pharmacogenomics, inspiring further investigations into genotype-guided dosing protocols.